Prudential Financial
NKTR icon

Prudential Financial’s Nektar Therapeutics NKTR Stock Holding History

Prudential Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,175
Closed -$22.2K – 2488
2025
Q1 		$22.2K Sell
2,175
-602
-22% -$7.87K ﹤0.01% 2250
2024
Q4 		$38.7K Sell
2,777
-974
-26% -$17.2K ﹤0.01% 2235
2024
Q3 		$73.1K Hold
3,751
– – ﹤0.01% 2606
2024
Q2 		$69.8K Buy
3,751
+1,071
+40% +$22.6K ﹤0.01% 2577
2024
Q1 		$37.6K Buy
2,680
+800
+43% +$8.38K ﹤0.01% 2617
2023
Q4 		$15.9K Buy
1,880
+507
+37% +$3.84K ﹤0.01% 2624
2023
Q3 		$12.3K Buy
+1,373
New +$13.2K ﹤0.01% 2581
2023
Q2 		– Sell
-12,106
Closed -$127K – 2674
2023
Q1 		$127K Sell
12,106
-440
-4% -$13.3K ﹤0.01% 2437
2022
Q4 		$425K Sell
12,546
-120
-0.9% -$5.81K ﹤0.01% 2092
2022
Q3 		$608K Sell
12,666
-171
-1% -$10.2K ﹤0.01% 1986
2022
Q2 		$732K Buy
12,837
+443
+4% +$28K ﹤0.01% 1942
2022
Q1 		$1M Sell
12,394
-180
-1% -$26.6K ﹤0.01% 1870
2021
Q4 		$2.55M Buy
12,574
+11,467
+1,036% +$2.49M ﹤0.01% 1398
2021
Q3 		$298K Sell
1,107
-43
-4% -$10.3K ﹤0.01% 2325
2021
Q2 		$296K Sell
1,150
-483
-30% -$134K ﹤0.01% 2311
2021
Q1 		$490K Buy
1,633
+24
+1% +$7.47K ﹤0.01% 2141
2020
Q4 		$411K Sell
1,609
-3
-0.2% -$775 ﹤0.01% 2138
2020
Q3 		$401K Sell
1,612
-19
-1% -$5.98K ﹤0.01% 2043
2020
Q2 		$567K Sell
1,631
-6,484
-80% -$2.02M ﹤0.01% 1874
2020
Q1 		$2.17M Buy
8,115
+476
+6% +$147K ﹤0.01% 1328
2019
Q4 		$2.47M Sell
7,639
-2,370
-24% -$687K ﹤0.01% 1507
2019
Q3 		$2.73M Sell
10,009
-104
-1% -$38.1K ﹤0.01% 1415
2019
Q2 		$5.4M Sell
10,113
-86
-0.8% -$43.1K 0.01% 1110
2019
Q1 		$5.14M Sell
10,199
-1,546
-13% -$916K 0.01% 1124
2018
Q4 		$5.79M Buy
11,745
+367
+3% +$222K 0.01% 1033
2018
Q3 		$10.4M Buy
11,378
+35
+0.3% +$29.9K 0.02% 903
2018
Q2 		$8.31M Sell
11,343
-186
-2% -$214K 0.01% 1015
2018
Q1 		$18.4M Sell
11,529
-5,717
-33% -$7.37M 0.03% 636
2017
Q4 		$15.4M Sell
17,246
-100
-0.6% -$59.1K 0.02% 744
2017
Q3 		$6.24M Sell
17,346
-331
-2% -$104K 0.01% 1054
2017
Q2 		$5.18M Buy
17,677
+194
+1% +$56.1K 0.01% 1122
2017
Q1 		$6.16M Buy
17,483
+193
+1% +$43.4K 0.01% 1033
2016
Q4 		$3.18M Buy
17,290
+1,216
+8% +$247K 0.01% 1314
2016
Q3 		$4.14M Sell
16,074
-5,834
-27% -$1.5M 0.01% 1164
2016
Q2 		$4.68M Buy
21,908
+376
+2% +$84K 0.01% 1148
2016
Q1 		$4.44M Buy
21,532
+1,007
+5% +$193K 0.01% 1153
2015
Q4 		$5.19M Buy
20,525
+507
+3% +$104K 0.01% 1057
2015
Q3 		$3.29M Buy
20,018
+440
+2% +$77.8K 0.01% 1224
2015
Q2 		$3.67M Buy
19,578
+18,820
+2,483% +$3.24M 0.01% 1258
2015
Q1 		$125K Sell
758
-17,587
-96% -$3.61M ﹤0.01% 2176
2014
Q4 		$4.26M Sell
18,345
-400
-2% -$85.5K 0.01% 1079
2014
Q3 		$3.39M Buy
18,745
+9,481
+102% +$1.81M 0.01% 1140
2014
Q2 		$1.78M Buy
9,264
+7,892
+575% +$1.4M ﹤0.01% 1575
2014
Q1 		$249K Buy
1,372
+447
+48% +$88.5K ﹤0.01% 2106
2013
Q4 		$157K Sell
925
-60
-6% -$9.68K ﹤0.01% 2206
2013
Q3 		$154K Buy
985
+13
+1% +$2.4K ﹤0.01% 2193
2013
Q2 		$168K Buy
+972
New +$149K ﹤0.01% 2188

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prudential Financial's NKTR Position: Q2 2025 in Review

Prudential Financial sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 2,175 shares — an estimated $22.2K sold.

Prudential Financial first reported a position in NKTR in Q2 2013 and held it in 47 quarters. The position peaked at $18.4M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Prudential Financial reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prudential Financial sold 2,175 Nektar Therapeutics shares in Q2 2025, an estimated $22.2K.
  • Prudential Financial first reported a position in Nektar Therapeutics in Q2 2013 and held it in 47 quarters.
  • Prudential Financial's Nektar Therapeutics position peaked at $18.4M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Prudential Financial's 13F filing for Q2 2025, filed 12 Aug 2025.